Case 2:13-cv-00391-ES-JAD Document 173 Filed 10/16/15 Page 1 of 12 PageID: 2205
`
`Karen A. Confoy
`Direct Dial: (609) 844-3033
`Email Address: kconfoy@foxrothschild.com
`
`October 16, 2015
`
`Mail: P.O. Box 5231, Princeton, NJ 08543-5231
`
`Princeton Pike Corporate Center
`997 Lenox Drive, Building 3
`Lawrenceville, NJ 08648-2311
`Tel 609.896.3600 Fax 609.896.1469
`www.foxrothschild.com
`
`VIA ECF AND HAND DELIVERY
`
`Honorable Joseph A. Dickson, U.S.M.J.
`United States District Court
`District of New Jersey
`Martin Luther King, Jr. Bldg. & U.S. Courthouse
`50 Walnut Street
`Newark, New Jersey 07101
`
`Re:
`
`Jazz Pharmaceuticals, Inc. v. Amneal Pharmaceuticals, LLC, et al.
`C.A. No. 2:13-cv-00391 (ES) (JAD) (Consolidated)
`
`Dear Judge Dickson:
`
`together with Knobbe, Martens, Olson & Bear, LLP, represent
`The undersigned,
`Defendants Sun Pharmaceutical Industries Ltd., Ohm Laboratories Inc., and Ranbaxy Inc.
`(“Sun”) in the above-referenced matter. We write concerning letters sent by Plaintiff Jazz
`Pharmaceuticals, Inc. (“Jazz”) on September 30, 2015 (“Jazz’s Letter”) and Defendant Par
`Pharmaceutical, Inc. (“Par”) on October 9, 2015 (“Par’s Letter”) regarding Jazz’s request for
`production of documents. Defendant Watson Laboratories Inc. (“Watson”) sent a letter to the
`Court on October 15, 2015 (“Watson’s Letter”) to confirm that those letters do not concern
`Watson. The undersigned likewise write to confirm our understanding that Jazz’s Letter and
`Par’s Letter do not concern Sun or the production of Sun documents.
`
`On September 30, 2015, Sun received a copy of Jazz’s Letter, which, aside from the
`opening and closing remarks, was redacted in its entirety. See Exhibit A. The un-redacted
`portions of the letter made an ambiguous request that the Court order “Defendants” to produce
`FDA correspondence. Id. Nothing in the un-redacted portion of Jazz’s Letter indicates which
`“Defendants” are the subject of Jazz’s Letter. Jazz has not separately informed Sun that it is
`seeking to compel the production of Sun documents, and no further discussion between Jazz and
`Sun concerning the matter has taken place.
`
`

`

`Case 2:13-cv-00391-ES-JAD Document 173 Filed 10/16/15 Page 2 of 12 PageID: 2206
`
`Honorable Joseph A. Dickson, U.S.M.J.
`October 16, 2015
`Page 2
`
`On October 9, 2015, Sun received a redacted copy of Par’s Letter that was sent to the
`Court in response to Jazz’s Letter. See Exhibit B. Although the undersigned have not seen un-
`redacted versions of either Jazz’s Letter or Par’s Letter, it is our understanding that the letters
`cannot concern Sun or the production of Sun documents. There is no pending motion to compel
`FDA correspondence from Sun, nor could there be as there has been no meet and confer between
`Jazz and Sun and any such motion would be premature. Also, to the extent Jazz’s Letter is
`directed to Sun,
`this would appear to be a violation of paragraph 17 of the Discovery
`Confidentiality Order (See Dkt. No. 144), which prohibits the use of one party’s confidential
`information in support of a claim or defense against another party.
`
`Therefore, we respectfully request that any order that may be entered in response to Jazz’s
`Letter and Par’s Letter explicitly exempt Sun or the production of Sun documents from its scope.
`We thank the Court for its attention to this matter.
`
`Respectfully submitted,
`
`/s/ Karen A. Confoy
`
`Karen A. Confoy
`
`KAC:nmn
`Enclosure
`cc:
`All Counsel of Record
`
`

`

`Case 2:13-cv-00391-ES-JAD Document 173 Filed 10/16/15 Page 3 of 12 PageID: 2207
`Case 2:13-cv-00391-ES-JAD Document 173 Filed 10/16/15 Page 3 of 12 PageID: 2207
`
`EXHIBIT A
`
`EXHIBIT A
`
`
`
`

`

`Case 2:13-cv-00391-ES-JAD Document 173 Filed 10/16/15 Page 4 of 12 PageID: 2208
`
`Charles M. Lizza
`Phone: (973) 286-6715
`Fax: (973) 286-6815
`clizza@saul.com
`www.saul.com
`
`September 30, 2015
`
`Contains Highly Confidential
`Information Subject to
`Discovery Confidentiality Order
`
`VIA ECF & FEDEX
`
`The Honorable Joseph A. Dickson, U.S.M.J.
`United States District Court
`Martin Luther King, Jr. Federal Building
`50 Walnut Street, Room 2060
`Newark, New Jersey 07102
`
`Re:
`
`Jazz Pharmaceuticals, Inc., et al. v. Amneal Pharmaceuticals, LLC, et al.
`Civil Action No. 13-391 (ES)(JAD)(consolidated)
`
`Dear Judge Dickson:
`
`This firm, together with Quinn Emanuel Urquhart & Sullivan, LLP and Richard G. Greco
`PC, represents plaintiffs Jazz Pharmaceuticals, Inc. and Jazz Pharmaceuticals Ireland Limited
`(collectively, “Jazz”) in the above-referenced matter. We write regarding Jazz’s request that the
`Court compel Defendants to produce FDA correspondence withheld in violation of Local Patent
`Rule 3.6(j). See D.I. 85, 90, 97.
`
`One Riverfront Plaza, Suite 1520  Newark, NJ 07102-5426  Phone: (973) 286-6700  Fax: (973) 286-6800
`
`D E L A W A R E M A R Y L A N D M A S S A C H U S E T T S N E W J E R S E Y N E W Y O R K P E N N S Y L V A N I A W A S H I N G T O N , D C
`
`A DELAWARE LIMITED LIABILITY PARTNERSHIP
`
`

`

`Case 2:13-cv-00391-ES-JAD Document 173 Filed 10/16/15 Page 5 of 12 PageID: 2209
`Case 2:13-cv-00391-ES-JAD Document 173 Filed 10/16/15 Page 5 of 12 PageID: 2209
`
`September 30, 2015
`
`Page 2
`
`
`
`1 y request t at t e C01u1 or er
`Accor mg y, we respect
`Defendants to innnediately produce the improperly withheld FDA correspondence.
`
`Thank you for Your Honor’s kind attention to this matter.
`
`Respectfully yours,
`
`@410. ct £551
`
`Charles M. Lizza
`
`Exhibits
`
`cc:
`
`All Counsel (via e-n1ail)
`
`

`

`Case 2:13-cv-00391-ES-JAD Document 173 Filed 10/16/15 Page 6 of 12 PageID: 2210
`
`EXHIBIT 1
`
`Confidential Material Redacted
`Pursuant to L. Civ. R. 5.3(c)(3)
`Filed Under Seal Pursuant to the Court's
`March 20, 2015 Order (D.I. 119)
`
`

`

`Case 2:13-cv-00391-ES-JAD Document 173 Filed 10/16/15 Page 7 of 12 PageID: 2211
`
`EXHIBIT 2
`
`Confidential Material Redacted
`Pursuant to L. Civ. R. 5.3(c)(3)
`Filed Under Seal Pursuant to the Court's
`March 20, 2015 Order (D.I. 119)
`
`

`

`Case 2:13-cv-00391-ES-JAD Document 173 Filed 10/16/15 Page 8 of 12 PageID: 2212
`Case 2:13-cv—00391—ES-JAD Document 173 Filed 10/16/15 Page 8 of 12 PageID: 2212
`
`EXHIBIT B
`
`EXHIBIT B
`
`
`
`

`

`Case 2:13-cv-00391-ES-JAD Document 173 Filed 10/16/15 Page 9 of 12 PageID: 2213
`Case 2:13-cv-00391-ES-JAD Document 173 Filed 10/16/15 Page 9 of 12 PageID: 2213
`
`Sean R. Kelly
`(973) 6224801
`skelly_@saiber.com
`
`Sd’lber
`
`ATTORNEYS AT LAW
`
`October 9, 2015
`
`CONTAINS HIGHLY CONFIDENTIAL INFORMATION—
`SUBJECT TO DISCOVERY CONFIDENTIALITY ORDER
`
`BY ELECTRONIC FILING
`
`The Honorable Joseph A. Dickson, U.S.M.J.
`United States District Court
`
`Martin Luther King Jr. Federal Courthouse
`Newark, New Jersey 07101
`
`Re:
`
`Jazz Pharmaceuticals, Inc. v. Amneal Pharmaceuticals, LLC et a].
`CA. No. 13-cv-391 (ESngADMConsolidatedl
`
`Dear Judge Dickson:
`
`This firm, together with Arent Fox LLP, represents Par Pharmaceutical, Inc. (“Par”) in
`the above~captioned consolidated matter. We write in response to Jazz’s September 30, 201.5
`letter
`(“Jazz’s Letter”)
`requesting the Court
`to compel Defendants
`to produce FDA
`correspondence allegedly withheld in violation of Local Patent Rule 3.66). Specifically, Jazz
`requests that the Court u5e Par’s confidential correspondence with the FDA as a basis to compel
`further production of FDA correspondence from the other defendants in the above-captioned
`consolidated matter (cg. Amneal and Watson Laboratories, Inc.). Such a request, however, is
`still premature.
`
`As an initial matter, we note that the timing of Jazz’s re uest for Defendants’ FDA
`
`corres ondence is highly sus ect. As Your Honor ma recall
`
`information from Defendants -
`is attempting to obtain any and all
`Jazz, no doubt,
`_This explains Jazz’s efforts to use Par’s
`confidential FDA correspondence as a basis to request all Defendants’ correSpondence with the
`
`FDA. Accordinili, Jazz’s reiucst should be seen for what it is: a transiarent and eager attempt
`
`
`Salber LLC - 1.8 Columbia Turnpike ' Suite 200 - Florham Park, New Jersey - 07932 u Tel 973.622.3333 - Fax 973.622.3349 - www.5aiber.com
`Florham Park ' Newark - New York
`- Atlantic City ' Point Pleasant Beach
`
`

`

`Case 2:13-cv-00391-ES-JAD Document 173 Filed 10/16/15 Page 10 of 12 PageID: 2214
`
`The Honorable Joseph A. Dickson, U.S.M.J.
`October 9, 2015
`Page 2
`
`Furthermore the fact that
`
`Moreover, and further to our October 16, 2014 correspondence (EC'F No. 87), Jazz’s
`repeated allegations that Defendants have violated Local Patent Rule 3.60) are misguided and
`untrue. L. Pat. R. 3.6 (i) simply requires that “[e}ach party that has an ANDA application
`pending .
`.
`. provide a copy of all correSpondence between itself and the FDA pertainin to the
`endin ANDA a lication . ”
`See L P t R. 3 6 '
`emhasis added .
`
`
`
`
`
`_ Jazz cannot suffer any
`prejudice or harm through Defendants’ withholding of the documents in question, and in fact
`underscores that such documents are at this time irrelevant to infrinement of the atents-in-
`suit.
`
`‘
`
`

`

`Case 2:13-cv-00391-ES-JAD Document 173 Filed 10/16/15 Page 11 of 12 PageID: 2215
`Case 2:13-cv-00391-ES-JAD Document 173 Filed 10/16/15 Page 11 of 12 PageID: 2215
`
`The Honorable Joseph A. Dickson, U.S.M.J.
`October 9, 2015
`Page 3
`
`Accordingly, we respectfully request that the Court deny Jazz’s request to im
`
`'
`
`comiel the production ofthe FDA correspondence Defendants have withheld
`
`We thank the Court for its consideration in this matter.
`
`Respectfully yours,
`
`5/ Sean R. Kell
`
`Sean R. Kelly
`
`Enclosure
`
`cc: All counsel (Via e—mail)
`
`

`

`Case 2:13-cv-00391-ES-JAD Document 173 Filed 10/16/15 Page 12 of 12 PageID: 2216
`Case 2:13-cv-00391-ES-JAD Document 173 Filed 10/16/15 Page 12 of 12 PageID: 2216
`
`EXHIBIT 1 «- FILED UNDER SEAL
`
`